Pathogenesis of Primary Biliary Cholangitis

原发性胆汁性胆管炎的发病机制

• 批准号: 10095117
• 负责人: KONSTANTINOS N LAZARIDIS
• 金额: $ 62.87万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-12-21 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10095117
• 关键词: Architecture; Artificial Intelligence; Autoimmune; Autoimmunity; Automobile Driving; Biological; Biological Assay; Biology; Blood; Caring; Cellular Immunity; Chemicals; Clinic; Clinical; Collection; Cytometry; Data; Development; Dimensions; Disease; Disease Progression; Environment; Evaluation; Funding; Genomics; Goals; Hand; Heel; Immune; Immune system; Immunity; Individual; Inflammatory; Investigation; Knowledge; Light; Liver; Liver diseases; Machine Learning; Mass Spectrum Analysis; Measures; Mediating; Metabolic; Metabolism; Methods; Molecular Profiling; Onset of illness; Pathogenesis; Pathogenicity; Pathologic Processes; Pathway interactions; Patients; Peripheral; Pharmacology; Phenotype; Pilot Projects; Positioning Attribute; Primary biliary cirrhosis; Process; Proteins; Publications; Questionnaires; Research Design; Resolution; Resources; Risk; Role; Sampling; Severity of illness; Specimen; Statistical Mechanics; Subgroup; System; Testing; Therapeutic; Toxic Environmental Substances; Universities; Work; advanced disease; base; biobank; cell free DNA; clinically relevant; combinatorial; effective therapy; genomic locus; improved; innovation; insight; metabolome; methylome; multidisciplinary; multiple omics; new therapeutic target; novel; novel strategies; novel therapeutics; patient oriented; quantum; response; toxin metabolism; transcriptome; translational study

PROJECT SUMMARY/ABSTRACT The major goal of this proposal is to conduct the first multi-omics translational study of Primary Biliary Cholangitis (PBC), thereby identifying the systems-level networks driving pathological processes in this rare, autoimmune liver disease. Improved understanding of PBC pathogenesis is urgently needed to inform tailored care and the development of new effective therapies. Comprehensive assessments of immunity and the role of environmental influence in PBC are currently lacking. Such evaluations would provide critical knowledge to leverage recent advances in the field’s ability to pharmacologically alter the immune system, thereby providing new hope to PBC patients. Having made significant contributions to the understanding of the genomic architecture underlying development of autoimmunity in PBC, we propose a novel, patient-oriented, multi- omics approach. In this new application, we will decipher how peripheral cellular immunity and non-cellular circulating factors contribute to PBC pathogenesis. We hypothesize that multi-omic analyses integrating cellular and non-cellular factors will identify systems-level pathways driving PBC pathogenesis. To test this hypothesis, we develop an innovative platform that combines aspects of machine learning and quantum statistical mechanics to identify omics-based signatures of PBC that when integrated with clinical features will unveil biological pathways driving disease pathogenesis. To perform this multi-omic study of PBC, we have assembled a world-class, multi-disciplinary team synergizing expertise in PBC biology and omics-scale analytics as well as resources across Mayo Clinic and Columbia University. With a new, in-hand collection of diverse biological specimens from 300 deeply- phenotyped PBC patients and 300 well-matched controls, our studies are already underway with preliminary data demonstrating measureable immunome, methylome, inflammatory protein, exposome, and metabolome differences between PBC patients and controls. In Aim 1, we thoroughly evaluate peripheral immune composition (the immunome) and activation state (methylome, transcriptome, inflammatory proteins) using mass-cytometry (CyTOF), sequencing- and proximity extension-based methods. In Aim 2, we perform a cutting-edge study of exogenous chemicals “the exposome” and endogenous metabolites “the metabolome” using ultrahigh resolution mass spectroscopy to discover pathogenic alterations in metabolism in PBC. We also develop an assay to quantify liver-specific cell-free DNA in blood as a measure of disease severity. In Aim 3, we integrate omic-specific signatures (Aims 1 and 2) using a novel approach to identify and prioritize PBC- associated features for further biological investigation. We then infer clinically-relevant subgroups of PBC patients by performing similarity network fusion analysis. In summary, using state-of-the-art, multi-omic analyses, we will discover systems-level networks driving PBC pathogenesis, spurring development of new hypotheses and studies designed to elucidate PBC pathobiology and identify novel therapies.

项目总结/文摘